Table 1.

Anti-HIV-1 activity of TXU (anti-CD7)-PAP in Hu-PBL-SCID micea

Treatment (dose [μg])Total no. of SCID MiceNo. of Hu-PBL-SCID mice with following HIV status by PCR and culture/total no. of Hu-PBL-SCID mice:
PCR+Cx+PCR+Cx+PCR+CxPCR+CxNDPCRCxPCRND Cx+
PBS2316/1616/1710/111/116/60/116/6
TXU (anti-CD7)-PAP
 10100/10NDNDND0/10NDND
 20100/10NDNDND0/10NDND
B53 (anti-CD4)-PAP
 1055/5NDNDND5/5NDND
 2043/40/30/33/31/10/3ND
 40183/180/110/112/111/79/11ND
 6050/30/50/30/3ND3/30/2
B43 (anti-CD19)-PAP, 2055/5NDNDND5/5NDND
AZT104/104/84/84/80/20/8ND
Control Hu-PBL-SCID mice (no HIV infection, no treatment)170/90/160/80/80/18/80/8
Control SCID mice (No Hu-PBL, HIV infection, no treatment)30/3NDNDND0/3NDND
  • a Hu-PBL-SCID mice were inoculated with clinical HIV-1 isolates in a biosafety level 3 containment facility. TXU-PAP immunoconjugate was administered intraperitoneally by injecting half of the total dose as an intraperitoneal bolus dose and delivering the remainder of the total dose over 2 weeks by using Alzet micro-osmotic pumps (regimen A) (n = 5) or by administering the total dose by daily intraperitoneal injections over a 5-day treatment period (regimen B) (n = 5). B53-PAP was administered by daily intraperitoneal injection over a 5-day treatment period when it was used at a dose of 10 or 20 μg. Mice receiving 40 or 60 μg of B53-PAP received 20 μg of the dose as an intraperitoneal bolus injection and the remainder over 2 weeks by using the Alzet micro-osmotic pumps. Two weeks after infection with HIV-1, Hu-PBL-SCID mice were electively killed and their peritoneal lavage cells as well as spleen cells were examined for evidence of infection by a culture assay for HIV-1 as well as by PCR amplification of a 115-bp DNA sequence in the gag region of the HIV-1 genome. In PBS-treated control Hu-PBL-SCID mice, culture assays for HIV were performed with spleen cells (n = 4) and with a mixture of peritoneal lavage and spleen cells (n = 12). PCR assays for HIV were performed with both spleen cells and peritoneal lavage cells except for two PBS-treated Hu-PBL-SCID mice, whose spleens were not examined by PCR. PCR+, PCR positive; Cx+, culture positive; PCR, PCR negative; Cx, culture negative; PCRND, PCR result was not determined; CxND, culture result was not determined; ND, not determined.